Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05961709 · ClinicalTrials.gov registry record · Phase 2
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
A Phase 2 study of Colon Cancer, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 5
- Study locations
NCT05961709 is a Phase 2 study of Colon Cancer that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 50 participants, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT05961709, a Phase 2 study of Colon Cancer, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 5
- Study locations
Study Summary
To learn if cemiplimab can help to control dMMR colon cancer.
Conditions Studied
Interventions
- DRUG Cemiplimab
Study Locations (5)
Arizona
- Banner - MD Anderson Cancer - Gilbert
Florida
- Baptist - MD Anderson Cancer Center - Jacksonville
Louisiana
- Ochsner - New Orleans
New Jersey
- Cooper University Medical Center - Camden
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-05-20 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05961709
The ClinicalTrials.gov registry entry for NCT05961709 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which Cemiplimab is the first listed.
NCT05961709 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Arizona, Florida, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05961709 about?
NCT05961709 is a clinical study titled "The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer". To learn if cemiplimab can help to control dMMR colon cancer.
What is the current status of trial NCT05961709?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-05-20. Estimated completion is 2028-04-30.
What conditions does trial NCT05961709 study?
This clinical trial studies the following conditions: Colon Cancer.
What interventions are being tested in trial NCT05961709?
The interventions under investigation include: Cemiplimab (DRUG).
Who is sponsoring clinical trial NCT05961709?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05961709 being conducted?
This trial has 5 study locations across Arizona, Florida, Louisiana, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Phase II Trial of Lung Chemoemobolization
RECRUITING · Phase 2
-
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
RECRUITING · Phase 2
-
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
RECRUITING · Phase 2
-
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Clinical Trial in Patients With Metastatic Colorectal Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.